GLP-1s

Page 2 of 2

Interest in GLP-1 medications like Ozempic will continue to grow given the multiple health conditions they can improve.
Commentary

The crisis over GLP-1 out-of-pocket costs deepens—it’s time for health-care leaders to step up

By
March 4, 2025
Close up of a man's face
Health

50-year-old security guard lost 70 pounds on Wegovy—then gained two pants sizes when he lost insurance coverage

By Tom Murphy and The Associated Press
February 24, 2025
Semaglutide medications Wegovy and Ozempic are pictured
Health

Wegovy, Ozempic shortage declared over, hitting copycats like Hims & Hers

By Bloomberg, Madison Muller, Ike Swetlitz and Naomi Kresge
February 21, 2025
A woman injects herself with medication.
Health

Ozempic, Wegovy maker calls out Hims & Hers Super Bowl ad: ‘Check before you inject’

By
February 11, 2025
Close-up of cast metal sign for the pharmaceutical company Merck
Health

Merck touts 20 new ‘blockbuster’ drugs in development with $50 billion potential

By
February 4, 2025
Novo Nordisk advertising logo on facade building, Danish pharmaceutical healthcare giant Novo Nordisk AS, production innovative drugs, obesity treatment Ozempic, Mainz, Germany June 15, 2024
Health

Investors are growing anxious about Novo Nordisk’s silence since disappointing CagriSema weight loss drug results

By
February 4, 2025
A person stands on a scale.
Health

Hims & Hers Super Bowl ad slams pricey pharma industry—and fumbles FDA warnings on compounded GLP-1 drugs

By
February 3, 2025
Ozempic and Wegovy medications side by side
Health

Ozempic and Wegovy surge to national approval with most U.S. adults considering it ‘a good thing’ to treat obesity

By The Associated Press, Kenya Hunter and Linley Sanders
January 31, 2025
The increase in online searches for obesity management drugs in recent years correlated to a surge in dispensed prescriptions, according to a new study from the Johns Hopkins Ciccarone Center for the Prevention of Cardiovascular Disease.
Health

Online searches predicted the surge in prescriptions of weight-loss drugs like Wegovy and Zepbound, study says. Here’s what could happen next

By
January 29, 2025
Eli Lilly & Co., the Fortune 500 pharma firm that manufactures weight-loss injection Zepbound (tirzepatide), has a comparable oral medication in the works that could be approved by the FDA as early as 2026, CEO Dave Ricks told Bloomberg TV on Jan. 13, 2025.
Health

Hate needles? Lilly’s weight-loss pill could get FDA approval next year, CEO says

By
January 22, 2025
Close up of RFK Jr. speaking against a blue background
Health

Health-care investors bank on Congress snarling RFK Jr.’s plans

By
January 17, 2025
Portrait of Crunch Fitness CEO Jim Rowley seated at Fortune's video studio.
Success

The CEO of Crunch Fitness doesn’t think there’s such a thing as work-life balance: ‘That’s for somebody who’s not fully committed’

By Jane Thier and Fortune Editors
January 16, 2025
A Walgreens store exterior with people walking by on the street
Retail

Walgreens CEO describes drawback of anti-shoplifting strategy: ‘When you lock things up…you don’t sell as many of them’

By
January 14, 2025

Most Popular